MyoKardia Inc. (NASDAQ:MYOK)’s share price traded down 0.2% during trading on Monday . The company traded as low as $21.14 and last traded at $21.60, with a volume of 76,917 shares traded. The stock had previously closed at $21.55.

A number of equities analysts recently commented on the company. Cowen and Company reiterated a “buy” rating on shares of MyoKardia in a research note on Friday, May 13th. Wedbush reiterated an “outperform” rating and issued a $22.00 price target on shares of MyoKardia in a research note on Thursday, May 12th. Zacks Investment Research downgraded MyoKardia from a “hold” rating to a “sell” rating in a research note on Wednesday, July 13th. BMO Capital Markets began coverage on MyoKardia in a research note on Wednesday, July 20th. They issued an “outperform” rating and a $28.00 price target for the company. Finally, Credit Suisse Group AG reissued a “buy” rating and issued a $20.00 target price (up previously from $16.00) on shares of MyoKardia in a report on Tuesday, July 12th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. MyoKardia currently has a consensus rating of “Buy” and a consensus price target of $23.50.

The stock has a 50-day moving average price of $17.76 and a 200 day moving average price of $12.73. The firm’s market cap is $590.12 million.

MyoKardia (NASDAQ:MYOK) last announced its earnings results on Tuesday, August 9th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.33) by $0.04. The firm had revenue of $3.55 million for the quarter, compared to the consensus estimate of $3.55 million. The company’s revenue for the quarter was up .0% compared to the same quarter last year. Equities analysts expect that MyoKardia Inc. will post ($1.50) EPS for the current fiscal year.

MyoKardia, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in the development of therapies for treating cardiovascular diseases. The Company focuses on developing and discovering therapies for hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.